Price movement over the last 24 hours
ARK Innovation ETF vs UnitedHealth Group Inc — how do they compare? ARK Innovation ETF trades at $79.8, while UnitedHealth Group Inc trades at $425.61 (market cap $385.62B). The key difference: UnitedHealth Group Inc pays a 2.19% dividend while ARK Innovation ETF pays none, and UnitedHealth Group Inc is trading nearer its 52-week high, ARK Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKK | UNH | |
|---|---|---|
52-Week High | $92.50 | $431.68 |
52-Week Low | $63.52 | $237.77 |
Market Cap | — | $385.62B |
Sector | — | Health |
Enterprise Value | — | $432.30B |
Dividend Yield | — | 2.19% |
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $7.23 versus $6.58 expected. Revenue grew to $447.57 billion in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
UNH presents a favorable risk-reward profile with 82.7% analyst buy ratings and a consensus price target of $423.18, near the current price. Key opportunities include demographic tailwinds from an aging population and tech-driven efficiency gains. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. The stock's valuation at a P/E of 31.97 requires sustained earnings growth to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →